Press release
Al Amyloidosis Market to Grow Positively at a Paltry CAGR During the Study Period | Janssen Pharmaceutical, Genmab, Prothena, and others
Al Amyloidosis Market
Download sample pages @ https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key highlights from the AL Amyloidosis market report:
The total number of AL Amyloidosis Incident cases associated with 7MM countries was approximately 8,600 in 2021.
The AL Amyloidosis market size in the seven major markets was ~USD 920 million in 2021.
AL Amyloidosis Epidemiology is segmented into total AL Amyloidosis Incident cases, AL Amyloidosis Gender Specific Cases, AL Amyloidosis Age-specific Cases, etc.
The leading companies working in the AL Amyloidosis Market include Janssen Pharmaceutical, Prothena, Alexion Pharmaceuticals, Oncopeptides AB, Bristol-Myers Squibb, and others.
Al Amyloidosis Overview
Amyloid light-chain (AL) amyloidosis, also known as primary amyloidosis, is the most common form of systemic amyloidosis. It originates in the bone marrow, the soft tissue inside the bones where blood-forming cells are produced, including cells that generate antibodies to combat infections. These cells can grow abnormally, leading to an excess of a protein called light chains. These light chains clump together and form amyloid deposits in major organs, causing progressive organ dysfunction (e.g., heart, kidney, liver). The risk of early death is a hallmark of severe AL amyloidosis.
Treatment for AL amyloidosis is highly individualized, based on factors such as age, organ dysfunction, and the toxicity of treatment regimens. It should be guided by biomarkers of hematologic and cardiac response. Alkylator-based chemotherapy is effective in nearly two-thirds of patients, but managing AL amyloidosis is challenging due to treatment-emergent side effects. Novel agents are also being investigated, and trials are ongoing to determine their optimal use.
Several unmet needs in the AL amyloidosis market include the lack of disease-specific curative therapies, the high cost of approved therapies, the need for safer therapies with minimal toxicity, the significant disease and economic burden, and the increasing incidence of the disease. These factors present opportunities for market growth and innovation.
Request for sample pages @ https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Al Amyloidosis Epidemiological Insights
The total number of AL Amyloidosis Incident cases associated with 7MM countries was approximately 8,600 in 2021.
Al Amyloidosis Treatment Market
Treatment for AL amyloidosis is highly individualized, taking into account factors such as age, the severity of organ damage/dysfunction, co-morbidities, and the toxicity of treatment regimens. It should be guided by biomarkers of hematologic and cardiac response. Alkylator-based chemotherapy is effective in nearly two-thirds of patients. Novel agents are also being investigated, and trials are ongoing to determine their optimal use.
Currently, bortezomib-based regimens (CyBorD-cyclophosphamide, bortezomib, and dexamethasone) are widely used as first-line therapy for AL amyloidosis in the US, EU, and Japan. Oral melphalan plus dexamethasone (MDex) has been a standard of care for many years in treating relapsing and refractory patients. In January 2021, the combination of daratumumab plus hyaluronidase (Darzalex Faspro) with bortezomib, cyclophosphamide, and dexamethasone received accelerated approval from the US FDA for newly diagnosed light chain (AL) amyloidosis. This regimen is likely to become the next standard of care for AL amyloidosis in the 7MM.
Promising Therapies in the Al Amyloidosis Pipeline
Daratumumab
Birtamimab
And others
Discover more about Al Amyloidosis therapies in the pipeline @ https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Leading Companies Working in the Al Amyloidosis Market
Janssen Pharmaceutical
Genmab
Prothena
And others
To understand key companies related to the Al Amyloidosis Market, get a snapshot of the Al Amyloidosis Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Scope of the Al Amyloidosis Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Al Amyloidosis Companies: Janssen Pharmaceutical, Genmab, Prothena, and others
Key Al Amyloidosis Pipeline Therapies: Daratumumab, Birtamimab, and others
Therapeutic Assessment: Al Amyloidosis current marketed and emerging therapies
Al Amyloidosis Market Dynamics: Al Amyloidosis market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Al Amyloidosis Market Access and Reimbursement
Table of Contents
1. Al Amyloidosis Market Key Insights
2. Al Amyloidosis Market Report Introduction
3. Al Amyloidosis Market Overview at a Glance
4. Al Amyloidosis Market Executive Summary
5. Disease Background and Overview
6. Al Amyloidosis Treatment and Management
7. Al Amyloidosis Epidemiology and Patient Population
8. Patient Journey
9. Al Amyloidosis Emerging Drugs
10. 7MM Al Amyloidosis Market Analysis
11. Al Amyloidosis Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Al Amyloidosis Market Drivers
15. Al Amyloidosis Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports by DelveInsight:
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market
Contact Us:
Kritika Rehani
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Al Amyloidosis Market to Grow Positively at a Paltry CAGR During the Study Period | Janssen Pharmaceutical, Genmab, Prothena, and others here
News-ID: 3634742 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Amyloid
Islet Amyloid Polypeptide Market Analysis Current Landscape and Future Outlook
The global Islet Amyloid Polypeptide market is projected to reach approximately USD 255.8 million by 2033, growing at a compound annual growth rate (CAGR) of 10.1% from 2024 to 2033.
Islet Amyloid Polypeptide Market Overview
The Islet Amyloid Polypeptide market is gaining traction due to its critical role in metabolic disorders, particularly in type 2 diabetes research and treatment. Islet Amyloid Polypeptide (IAPP), also known as amylin, is closely associated with insulin…
Cerebral Amyloid Angiopathy Pipeline Landscape: 10+ Emerging Therapies Targeting …
Cerebral Amyloid Angiopathy (CAA) is a progressive cerebral small vessel disease marked by amyloid-β (Aβ) protein deposition in the walls of leptomeningeal and cortical blood vessels. Often occurring in the elderly and closely linked with Alzheimer's disease, CAA contributes significantly to cognitive impairment, spontaneous intracerebral hemorrhage, and cerebral microbleeds. Despite its high clinical burden, there are currently no approved disease-modifying therapies specifically for CAA, and diagnosis remains challenging without advanced…
Amyloid Peptides Market to Witness Astonishing Growth by 2029
Amyloid Peptides Market is anticipated to grow at a significant CAGR during the forecast period. Growing favourable investment, as well as reimbursement facilities in the developed economic countries, is one of the major factors that is expected to fuel the global amyloid peptides market during the forecast period. Moreover, a growing number of clinical trials and research activities to develop treatment and drugs for Alzheimer's are also anticipated to boost…
Amyloid Peptides Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Amyloid Peptides Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Amyloid Peptides players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyloid Peptides with respect to individual growth…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
